Liminatus Pharma, Inc.
LIMN
$3.84
$0.205.35%
NASDAQ
| 06/30/2026 | 03/31/2026 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | 11.13% | -20.73% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 25.25% | 24.51% | |||
| Operating Income | -25.25% | -24.51% | |||
| Income Before Tax | -25.24% | 86.24% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -25.24% | 86.24% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -25.24% | 86.24% | |||
| EBIT | -25.25% | -24.51% | |||
| EBITDA | -25.26% | -24.52% | |||
| EPS Basic | 6.85% | 89.64% | |||
| Normalized Basic EPS | 6.09% | 15.82% | |||
| EPS Diluted | 6.85% | 89.64% | |||
| Normalized Diluted EPS | 6.09% | 15.82% | |||
| Average Basic Shares Outstanding | 34.44% | 32.84% | |||
| Average Diluted Shares Outstanding | 34.44% | 32.84% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||